Mostrar el registro sencillo del ítem
Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival
dc.contributor.author | Boughanem, H. | |
dc.contributor.author | Martin-Nunez, G. M. | |
dc.contributor.author | Torres, E. | |
dc.contributor.author | Arranz-Salas, I. | |
dc.contributor.author | Alcaide, J. | |
dc.contributor.author | Morcillo, S. | |
dc.contributor.author | Tinahones, F. J. | |
dc.contributor.author | Crujeiras Martínez, Ana Belén | |
dc.contributor.author | Macias-Gonzalez, M. | |
dc.date.accessioned | 2022-04-29T10:25:56Z | |
dc.date.available | 2022-04-29T10:25:56Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2075-4426 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/33187096 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16599 | |
dc.description.abstract | Recent studies suggest that long-interspersed nucleotide element-1 (LINE-1) hypomethylation is commonly found in colorectal cancer (CRC), and is associated with worse prognosis. However, the utility of LINE-1 methylation on the prognosis of CRC is still controversial, and may be due to the fact that some clinical and pathological features may affect LINE-1 methylation. Thus, the aim of this study was to assess the prognostic value of tumor LINE-1 methylation in CRC, through their association with the CRC clinical and pathological characteristics. Survival of sixty-seven CRC patients was evaluated according to the median of tumor LINE-1 methylation, as well as pathological and oncological variables. We also studied the association between LINE-1 methylation and pathological features, and finally, we assessed the overall and disease-free survival of LINE1 methylation, stratified by neoadjuvant treatment and further checked by multivariate Cox regression to assess the statistical interactions. LINE-1 was hypomethylated in the CRC tumor with respect to the tumor adjacent-free area (p < 0.05), without association with any other clinical and oncological features, nor with overall and disease-free survival rates for CRC. Relevantly, in neoadjuvant treatment, LINE-1 methylation was associated with survival rates. Thus, disease-free and overall survival rates of treated CRC patients were worse in the hypomethylated LINE-1 tumors than those with normal LINE-1 methylation (p = 0.004 and 0.0049, respectively). Indeed, LINE-1 was hypermethylated more in the treated patients than in the non-treated patients (p < 0.05). The present study showed that tumor LINE-1 hypomethylation was associated with worse survival rates in only treated patients. Our data suggest an interactive effect of neoadjuvant treatment and tumor LINE-1 methylation, which could be a specific-tissue biomarker to predict survival of the treated patients, and help to personalize treatment in CRC. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival | en |
dc.type | Journal Article | es |
dc.authorsophos | Boughanem, H.;Martin-Nunez, G. M.;Torres, E.;Arranz-Salas, I.;Alcaide, J.;Morcillo, S.;Tinahones, F. J.;Crujeiras, A. B.;Macias-Gonzalez, M. | |
dc.identifier.doi | 10.3390/jpm10040219 | |
dc.identifier.pmid | 33187096 | |
dc.identifier.sophos | 39538 | |
dc.issue.number | 4 | es |
dc.journal.title | JOURNAL OF PERSONALIZED MEDICINE | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | IDIS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 10 | es |